Neuromodulation Devices
Jan 15, 2026
Medtronic Diabetes Secures FDA Clearance for MiniMed Go™ Smart MDI Platform; Neurolief Achieves FDA PMA Approval for Novel At-Home Brain Stimulation Therapy for Depression; Haemonetics Completes Acquisition of Vivasure Medical Limited; Boston Scientific Enters Agreement to Acquire Valencia Technologies; Butterfly Medical Completes Pivotal Trial for Minimally Invasive BPH Therapy; TYBR Health Announces First U.S. Clinical Use of the B3 GEL™ System
Medtronic Diabetes Announced FDA Clearance for MiniMed Go™ Smart MDI System Featuring Instinct Sensor Made by Abbott On January 12, 2026, Medtronic, a global leader in healthcare technology, announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MiniMed Go™ app. The MiniM...
Read More...
Nov 27, 2025
Bracco Receives FDA Clearance for Additional Clinical Use of Max 3™ Syringeless MR Injector; RapidAI Broadens Clinical AI Portfolio with Five Newly Granted FDA Clearances; Ceribell Secures FDA 510(k) Clearance for Clarity® Algorithm in Neonatal Care; BD Introduces Surgiphor™ Irrigation System Across Europe to Enhance Surgical Patient Protection; Neurophet and The Florey Announce Strengthened Collaboration to Advance Alzheimer’s Diagnostic Solutions; VSI® Performs First-Ever Robotic Minimally Invasive Bertolotti’s Resection; BioWave® Demonstrates Safe and Effective Home-Based and War Injury Pain Relief in Latest Clinical Data
FDA Approved Expanded Indication for Max 3™ Syringeless MR Injector from Bracco On November 25, 2025, Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., announced that the U.S. Food and Drug Administration (FDA) expanded the indication for its Max 3™ Rapid Exchange and Syringeless Injector fo...
Read More...
Aug 14, 2025
Nyxoah Secures FDA Nod for Genio® System in OSA Treatment; FDA Grants First 510(k) Clearance to DeepSight™-Powered NeedleVue™ LC1 Ultrasound System; TITAN CSR® Retractor Tops U.S. Military List for Trauma Care in Deployed Settings; FDA Clears Myra Vision to Begin US IDE Study for Glaucoma; HistoIndex Advances Fibrosis Assessment with AI-Powered FibroSIGHT™ Plus; Gentuity Partners with GE HealthCare to Broaden Access to Cutting-Edge Intravascular Imaging
FDA Approves Nyxoah’s Genio® System for Treating Obstructive Sleep Apnea On August 08, 2025, Nyxoah SA, a medical technology company that developed breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, announced that the U.S. Food and Drug Administration (FDA) had a...
Read More...
Aug 07, 2025
SetPoint Medical Earns FDA Nod for First-of-Its-Kind Neuroimmune Modulation Therapy in RA; Body Vision Medical Secures Singapore Pre‑Market Approval for LungVision; BioLab Holdings Initiates Landmark Clinical Trial for Placental Membrane Therapies; Concept Medical Launches MAGICAL-SV IDE Trial; Frenova Enters Strategic Partnership to Push Boundaries in Kidney Precision Medicine; Demetra Acquires OrthoFundamentals and Establishes Global Spine Division
SetPoint Medical Received FDA Approval for Novel Neuroimmune Modulation Therapy for Rheumatoid Arthritis On July 31, 2025, SetPoint Medical, a company focused on developing therapies for individuals with chronic autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) approved its Se...
Read More...
Jun 19, 2025
Presidio Medical™ Gains IDE Nod for ULF™ Study, Names Dimas Jiménez CFO; Creo Medical Gains FDA Nod for SpydrBlade™ Flex, Paving Way for U.S. Launch; Penumbra Completes Patient Enrollment in Pivotal STORM-PE RCT; Adona Medical Completes Enrollment in First-in-Human Trial of Novel Interatrial Shunt for Heart Failure; Johnson & Johnson Launches TECNIS Odyssey Intraocular Lens in Europe, Middle East, and Canada for Enhanced Cataract Care; Philips Sets New Benchmark in POCUS Technology with Flash 5100 Launch
Presidio Medical™ Received IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer On June 12, 2025, San Mateo, California–Presidio Medical, Inc., a global clinical-stage medical device company, received Investigational New Drug (IDE)...
Read More...
Feb 13, 2025
Agiliti Launches Essentia; KUBTEC Introduces PICASSO Plus; FDA Clears Neuvotion’s NeuStim™ for Non-Invasive Hand Stimulation in Stroke & SCI Patients; Ibex Medical Analytics Achieves Milestone with FDA 510(k) Clearance; BlueWind Medical Reports Strong Two-Year Outcomes for Revi® System in Peer-Reviewed Study; Reprieve Cardiovascular’s FASTR Pilot Trial Shows Positive Outcomes, FDA Approves IDE for Next Phase
Agiliti Launched Essentia, an Innovative Multi-Acuity Hospital Bed that Helps Lower Patient Risk and Accelerate Mobility On February 11, 2025, Agiliti, a prominent manufacturer and provider of medical device solutions for the U.S. healthcare industry, introduced Essentia™, a versatile multi-acuity bed fram...
Read More...
Feb 06, 2025
Bioretec Ltd. Gains CE Mark for RemeOs™ Trauma Screw; HoneyNaps’ AI Sleep Diagnostic Software Achieves Recognition as the 73rd and 74th Innovative Medical Devices by South Korea’s MFDS; Movano Health Advances Clinical Trials for Innovative Non-Cuff Blood Pressure Monitor; IRB Approves PathMaker Neurosystems’ MyoRegulator® ALS Study; Aspen Medical Products Closes Deal to Acquire Advanced Orthopaedics; Surmodics Achieves Early Clinical Success with Pounce™ XL Thrombectomy System
Bioretec Ltd. Secured CE Mark Approval for RemeOs™ Trauma Screw, Enabling European Market Launch On January 31, 2025, Bioretec Ltd., a leader in absorbable orthopedic implants, successfully completed the CE mark approval process and began the commercialization of its RemeOs™ Trauma Screw product portfolio ...
Read More...
May 09, 2024
Monteris Smallest Brain Laser Probe Launch; Vesica Health’s AssureMDx Test Launch; Anaut’s Eureka α Japanese Regulatory Approval; Geneoscopy’s Labcorp-Partnered Colon Cancer Test FDA Approval; Novel Omeza® OCM™ Diabetic Foot Ulcers Results; LEO Pharma Phase III Plaque Psoriasis Trial Results
Monteris Launched Smallest Brain Laser Probe on the Market On May 01, 2024, Monteris Medical launched the NeuroBlate® NB3™ FullFire® 1.6mm laser probe, the company’s latest product line innovation for use with their market-leading NeuroBlate System. The NB3 laser probe, which integrates Monteris' patented coo...
Read More...
Apr 25, 2024
iVEAcare’s $27.5 Million Series A Funding; AI Medical Service Joint Research Agreement with Mahidol University; CERENOVUS Launched Catheter; Cochlear FDA Clearance for The Osia System; Immunovia Announced Positive Results From The Model-Development Study; Hyalex Orthopaedics First Patients Treatment
iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. i...
Read More...
Dec 28, 2023
Savara Introduced aPAP ClearPathTM; RaySearch Released RayStation 2024A; FDA Approved Expanded Label for CVRx Neuromod Tech; FDA Clearance to Masimo’s Baby Monitoring System; Kansas City Proton Institute’s Advanced MEVION S250i Proton Therapy System; Gore’s Arise II Pivotal Study of the Gore® Ascending Stent Graft
Savara Introduced aPAP ClearPathTM to detect Autoimmune Pulmonary Alveolar Proteinosis On December 21, 2023, Savara, a clinical stage biopharmaceutical company launched aPAP ClearPathTM, which is used by the physicians to obtain a conclusive diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
